Braveheart Bio Prices Upsized $382.5M IPO at $18/Share, Trading Tomorrow
Summary
Braveheart Bio priced its upsized IPO at $18.00 per share, selling 21.25 million shares for gross proceeds of $382.5 million. The clinical-stage biotech, focused on hypertrophic cardiomyopathy, will begin trading on Nasdaq tomorrow under ticker BRVE. The upsizing and pricing at the top of the expected range signal strong institutional demand for a company with no revenue yet. Underwriters have a 30-day option for an additional 3.19 million shares, which could push total proceeds above $440 million. This capital will fund development of lead candidate BHB-1893, a next-generation cardiac myosin inhibitor. The IPO's size and pricing reflect confidence in the HCM pipeline despite early-stage risk.
This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.